Bli medlem
Bli medlem

Du är här

2016-11-15

Saniona AB: Saniona publishes its interim report for the third quarter 2016

PRESS RELEASE

November 15, 2016

Financial highlights
Jan - Sep 2016 (Jan - Sep 2015)

* Net revenues were SEK 69.5 M (11.8 M)
* EBIT was SEK 19.2 M (-22.7 M)
* Earnings per share were SEK 0.70 (-1.07)
* Diluted earnings per share were SEK 0.70 (-1.07)

Q3 2016 (Q3 2015)

* Net revenues were SEK 50.6 M (2.0 M)
* EBIT was SEK 33.7 M (-10.9 M)
* Earnings per share were SEK 1.32 (-0.46)
* Diluted earnings per share were SEK 1.31 (-0.46)

Business highlights in Q3 2016
* Saniona and Boehringer Ingelheim signed collaboration agreement in
schizophrenia. Saniona may receive up to €90 million in milestone payments
including an upfront payment of €5 million upon signing of the agreement.
Furthermore, Saniona is eligible to receive royalties on worldwide net
sales of any resulting products under the collaboration.
* Three public grants awarded for research programs totaling SEK 5.3 million.

* Recruitment of the 60 patients in Phase 2a study for Tesomet in type 2
diabetes completed.
* Distribution of all Saniona's shares in Initiator Pharma to Saniona's
shareholders suggested to an extraordinary general meeting.
* Board member Anker Lundemose stepped down from the board of directors.

Significant events after the reporting period
* Distribution of all Saniona's shares held in Initiator Pharma to Saniona's
shareholders decided at an extra ordinary general meeting.
* Saniona postponed list change to Nasdaq Stockholm following advanced ruling
from the listing committee.
* Research milestone of about SEK 1.5 million obtained from The Michael J.
Fox Foundation for Parkinson's Research.
* Saniona and Upsher Smith extended research collaboration under the drug
discovery and development collaboration for neurological diseases, which
the parties signed in the beginning of 2016. Saniona expects to report
about SEK 7.5 million in revenues under this agreement in 2017.
* Saniona filed a clinical trial application in Czech Republic and Hungary
for the performance of a Phase 2a study for Tesomet in patients with
Prader-Willi Syndrome during the first half of 2017.

Comments from the CEO
"The significant agreement with Boehringer Ingelheim provides strategic
flexibility and opportunities for investments in our own programs. Third
quarter is closing with a substantial profit, which clearly shows the
strength in our business model. We are focusing our investments on Tesomet,
which is in phase 2 for type 2 diabetes. Our intention is to initiate an
additional Phase 2 study for Prader-Willi Syndrome in a near future," says
Jørgen Drejer, CEO of Saniona.

Read the complete Interim Report attached below.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957,
E-mail:tf@saniona.com

This information is information that Saniona (publ) is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was submitted for
publication, through the agency of the contact person set out above, at 08:00
CET on November 15, 2016.

About Saniona
Saniona is a research and development company focused on drugs for diseases of
the central nervous system, autoimmune diseases, metabolic diseases and
treatment of pain. The company has a significant portfolio of potential drug
candidates at pre-clinical and clinical stage. The research is focused on ion
channels, which makes up a unique protein class that enables and controls the
passage of charged ions across cell membranes. Saniona has ongoing
collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith
Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based
spinout Ataxion Inc. Saniona is based in Copenhagen, Denmark, where it has a
research center of high international standard. Saniona is listed at Nasdaq
First North Premier and has about 4,600 shareholders. Pareto Securities is
Certified Advisor for Saniona. The company's share is traded under the ticker
SANION. Read more at
www.saniona.com.

20161115 - Saniona Q3 Report 2016 - UK
http://hugin.info/172499/R/2056874/770497.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Saniona AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.